A double-blind trial of transfer factor vs placebo in multiple sclerosis patients.
A double-blind trial of the effect of transfer factor on multiple sclerosis patients was carried out. In a series of fifty-six multiple sclerosis patients treated with monthly injections of either transfer factor or placebo for 1 year, no beneficial effect of transfer factor was noted. In addition, none of the immunological and serological parameters studied (measles migration inhibition, measles HI titre or CSF immunoglobulin) changed as a result of transfer factor therapy. Histocompatibility typing and CSF IgG/TP ratios were correlated with the disease activity. Of interest was the finding that the presence of the DW2 antigen, when unassociated with HLA-B7 antigen, appeared to correlate with the mildest form of disease activity.
D000328:Adult; D002464:Cell Migration Inhibition; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006649:Histocompatibility Antigens / Q000032:analysis; D006650:Histocompatibility Testing; D006801:Humans; D007074:Immunoglobulin G / Q000134:cerebrospinal fluid; D008297:Male; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy*; D014165:Transfer Factor / Q000627:therapeutic use*
D006649:Histocompatibility Antigens; D007074:Immunoglobulin G; D014165:Transfer Factor